- Scholar Rock Holding Corp at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Q3 2023 Scholar Rock Holding Corp Earnings Call TranscriptNov 07, 2023$12.35 (+1.48%)Earnings
- Scholar Rock Holding Corp Overview of the Current Treatment Landscape and Unmet Needs of Patients with SMA TranscriptJul 12, 2023
- Scholar Rock Holding Corp at JPMorgan Healthcare Conference TranscriptJan 10, 2023
- Scholar Rock Holding Corp TOPAZ Phase 2 Clinical Trial Data TranscriptJun 17, 2022
- Scholar Rock Holding Corp at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- Scholar Rock Holding Corp at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 09, 2021
- Scholar Rock Holding Corp to Host KOL Discussing Apitegromab's Therapeutic Potential in Patients with SMA Call TranscriptJun 15, 2021
- Scholar Rock Holding Corp at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- Scholar Rock Holding Corp Annual Shareholders Meeting TranscriptMay 27, 2021
- Scholar Rock Holding Corp to Announce the 12-Month Top-line Results of TOPAZ Phase 2 Trial TranscriptApr 06, 2021
- Scholar Rock Holding Corp at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Scholar Rock Holding Corp to Discuss the SRK-015 TOPAZ Interim Analysis Results Conference Call TranscriptOct 27, 2020
- Scholar Rock Holding Corp at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 16, 2020
- Q2 2020 Scholar Rock Holding Corp Earnings Call TranscriptAug 07, 2020$14.07 (+2.25%)Earnings
- Scholar Rock Holding Corp Annual Shareholders Meeting TranscriptMay 29, 2020
- Scholar Rock Holding Corp at Morgan Stanley Healthcare Conference TranscriptSep 11, 2019
- Scholar Rock Holding Corp at Oppenheimer Healthcare Conference TranscriptMar 19, 2019
- Scholar Rock Holding Corp at Cowen Health Care Conference TranscriptMar 13, 2019
- Scholar Rock Holding Corp SRK-015 Interim Phase 1 Results and Phase 2 Trial Design Conference Call TranscriptFeb 26, 2019
Scholar Rock Holding Corp to Announce the 12-Month Top-line Results of TOPAZ Phase 2 Trial Transcript
Good day, and thank you for standing by. Welcome to the 12-month top-line results of TOPAZ Phase II trial. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Catherine Hu, Vice President of Investor Relations and Communications. Please go ahead.
Good morning, and thank you for joining us on today's call to review the 12-month top-line results from our apitegromab TOPAZ Phase II clinical trial of patients with Type 2 and Type 3 spinal muscular atrophy, or SMA.
The webcast slides for this call can be accessed on the Events and Presentations section of the Investor Relations page on the Scholar Rock website.
I wanted to note that we'll be making various statements about Scholar Rock's future expectations, plans and prospects that constitute forward-looking statements for the purposes of the safe harbor provisions under the Private
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)